NANOVIBRONIX ANNOUNCES RECEIPT OF NASDAQ LISTING DETERMINATION

ANNOUNCES RECEIPT OF NASDAQ LISTING DETERMINATION;

N.Y., September 2, 2022 - NanoVibronix, Inc., (NASDAQ: NAOV), a medical device company utilizing the Company's

proprietary and patented low intensity surface acoustic wave (SAW) technology, today announced that, on August 30, 2022, the Company

received notice from the Nasdaq Listing Qualifications Staff (the "Staff") indicating that, based upon the Company's

continued non-compliance with Nasdaq's minimum bid price requirement as of August 29, 2022, the Company securities would be subject

to delisting unless the Company timely requests a hearing before the Nasdaq Hearings Panel (the "Panel"). The Company plans

to timely request a hearing, which request will stay any further action by the Staff at least pending the issuance of the Panel's

decision following the hearing and the expiration of any extension that may be granted by the Panel.

Inc. (NASDAQ: NAOV) is a medical device company headquartered in Elmsford, New York, with research and development in Nesher, Israel,

focused on developing medical devices utilizing its patented low intensity surface acoustic wave (SAW) technology. The proprietary technology

allows for the creation of low-frequency ultrasound waves that can be utilized for a variety of medical applications, including for disruption

of biofilms and bacterial colonization, as well as for pain relief. The devices can be administered at home without the assistance of

medical professionals. The Company's primary products include PainShield and UroShield , which are portable devices suitable

for administration at home without assistance of medical professionals. Additional information about NanoVibronix is available at: www.nanovibronix.com.

press release contains "forward-looking statements." Such statements may be preceded by the words "intends,"

"may," "will," "plans," "expects," "anticipates," "projects,"

"predicts," "estimates," "aims," "believes," "hopes," "potential"

or similar words. Forward-looking statements are not guarantees of future performance, are based on certain assumptions and are subject

to various known and unknown risks and uncertainties, many of which are beyond the Company's control, and cannot be predicted or

quantified; consequently, actual results may differ materially from those expressed or implied by such forward-looking statements. Such

risks and uncertainties include, without limitation, risks and uncertainties associated with: (i) the geographic, social and economic

impact of COVID-19 on the Company's ability to conduct its business and raise capital in the future when needed, (ii) market acceptance

of our existing and new products or lengthy product delays in key markets; (iii) negative or unreliable clinical trial results; (iv)

inability to secure regulatory approvals for the sale of our products; (v) intense competition in the medical device industry from much

larger, multinational companies; (vi) product liability claims; (vii) product malfunctions; (viii) our limited manufacturing capabilities

and reliance on subcontractor assistance; (ix) insufficient or inadequate reimbursements by governmental and/or other third party payers

for our products; (x) our ability to successfully obtain and maintain intellectual property protection covering our products; (xi) legislative

or regulatory reform impacting the healthcare system in the U.S. or in foreign jurisdictions; (xii) our reliance on single suppliers

for certain product components, (xiii) the need to raise additional capital to meet our future business requirements and obligations,

given the fact that such capital may not be available, or may be costly, dilutive or difficult to obtain; (xiv) our conducting business

in foreign jurisdictions exposing us to additional challenges, such as foreign currency exchange rate fluctuations, logistical and communications

challenges, the burden and cost of compliance with foreign laws, and political and/or economic instabilities in specific jurisdictions;

and (xv) market and other conditions. More detailed information about the Company and the risk factors that may affect the realization

of forward-looking statements is set forth in the Company's filings with the Securities and Exchange Commission (SEC), including

the Company's Annual Report on Form 10-K and its Quarterly Reports on Form 10-Q. Investors and security holders are urged to read

these documents free of charge on the SEC's web site at: http://www.sec.gov. The Company assumes no obligation to publicly

update or revise its forward-looking statements as a result of new information, future events, or otherwise, except as required by law.

Maas, Managing Principal, Hayden IR, LLC